CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00056990" target="_blank" >RIV/00216224:14110/11:00056990 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
čeština
Original language name
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Original language description
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Czech name
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Czech description
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Classification
Type
O - Miscellaneous
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9676" target="_blank" >NS9676: The influence of pharmacogenetic and pharmacokinetic factors on the efficacy and safety of the first schizophrenia episodes therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů